FAPI PET for Lung Fibrosis

About

Brief Summary

This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD).

The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease with fibrotic lesions who are scheduled to undergo lung biopsy or transplantation. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.

Primary Purpose

Diagnostic

Study Type

Interventional

Phase

Pilot/Feasibility

Eligibility

Gender

All

Healthy Volunteers

Minimum Age

18 Years

Maximum Age

N/A

Inclusion Criteria:

Patients with the following ILD:

Idiopathic interstitial pneumonia
Connective tissue disease related intestitial lung disease (CTD-ILD)
Drug-induced pneumonitis
Hypersensitivity pneumonitis
Radiation pneumonitis
Pneumoconiosis
Post-COVID-19 pulmonary fibrosis Patients with fibrotic lung lesion confirmed by HRCT performed within 6 months. Patients who are scheduled to undergo tissue biopsy or surgery of the lung. Patients are ≥ 18 years old at the time of the radiotracer administration. Patient can provide written informed consent.

Exclusion Criteria:

Patient is pregnant or nursing. Patients with active infectious lung disease. Patients not expected to comply with the protocol requirements, not able to understand or follow trial procedures

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you